RT Journal Article SR Electronic T1 Clinical resuts of therapy for non-tuberculous myocardium avium complex -Multicentric retrospective study of 581 patients in Japan JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA2680 DO 10.1183/13993003.congress-2015.PA2680 VO 46 IS suppl 59 A1 Shuichi Yano A1 Kazunari Tsuyuguchi A1 Katsuhiro Suzuki A1 Toumei Ogawa A1 Katsuo Yamada A1 Masaji Okada A1 Norimasa Ito YR 2015 UL http://erj.ersjournals.com/content/46/suppl_59/PA2680.abstract AB The clinical evidence of effect of medical treatment for Mycobacterium avium Complex patient is still limited.Methods Two handred sixty four patients in 16 facilities in Japan with primary therapy for Mycobacterium avium Complex lung disease with combination of Clarythromycin, Ethanbutol, Refanpicin, or other medicine was corrected retrospectively and analyzed its results. Microbiological culture results of sputum were analyzed as Primary endopoint.Results: The mean age was 65+/-12, 74 were male and 188 were female.197 patients had clinical symptons and 67 patients had no symptons. 30 patients had mixed infections. 192 patients were treated primarily with Clarythromycin, Refanpicin, and Ethanbutol (REC) +/- other antibiotics. Patients with symptons had less culture negative than with no symptons (50% vs 68%,p=0.0094), Patients with other pulmonary infectious disease had more culture positive (64% vs 54%, p=0.037). Patients treated with REC to the end had more culture negative (62% vs 49%, p=0.0041). 5 year survival rate was beter in culture negative petients than in culture positive patients (93.4% vs 77.8%)Conclusion: There is a possibility that REC might be a better regimen than others. We are still collecting retrospective cases up to 490 and we are now undergoing prospective study for analysing clinical results of REC treatment for patients with MAC lung desease.